Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Eligible participants with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck will be treated with reirradiation combined with anti-PD-1 mAb MK-3475 (generic name: pembrolizumab, trade name Keytruda®).
Inclusion criteria
- Recurrent Head and Neck Cancer,Carcinoma, Squamous Cell of Head and Neck